<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714569</url>
  </required_header>
  <id_info>
    <org_study_id>16417</org_study_id>
    <secondary_id>I8Q-MC-GSEA</secondary_id>
    <nct_id>NCT02714569</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this two-part study is to evaluate the safety and tolerability of the study&#xD;
      drug known as LY3202328 in healthy overweight participants in Part A, and those with&#xD;
      dyslipidemia (abnormal blood fats) in Part B.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">February 15, 2017</completion_date>
  <primary_completion_date type="Actual">February 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Part A is a crossover. Part B is a parallel assignment.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B</measure>
    <time_frame>Baseline, Up to 42 Days</time_frame>
    <description>Number of participants with one or more SAEs in Part A and Part B. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part A After a Single Dose</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose</time_frame>
    <description>Pharmacokinetics (PK) is the maximum plasma concentration (Cmax) of LY3202328 Part A after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Steady State Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part B</measure>
    <time_frame>Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
    <description>PK is the maximum plasma concentration of LY3202328 (Cmax) at steady state in Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Serum Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY3202328 (LY) in Part A After a Single Dose</measure>
    <time_frame>Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose</time_frame>
    <description>PK is the area under the serum concentration time curve from zero to Infinity (AUC[0-∞]) of LY3202328 in Part A after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Steady State Area Under the Serum Concentration-Time Curve During the Dosing Interval (AUCτ) of LY3202328 (LY) in Part B</measure>
    <time_frame>Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
    <description>PK is the area under the serum concentration-time curve (AUCτ) of LY3202328 at steady state during the dosing interval in Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time to Maximum Concentration (Tmax) of LY3202328 (LY) in Part A</measure>
    <time_frame>Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose</time_frame>
    <description>PK is the time to maximum concentration (Tmax) of LY3202328 in Part A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Steady State Tmax of LY3202328 (LY) in Part B</measure>
    <time_frame>Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
    <description>PK is the Tmax of LY3202328 at steady state in Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Change From Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A</measure>
    <time_frame>Predose, 24, 48, 96 Hours Postdose</time_frame>
    <description>Pharmacodynamics (PD) is the change from Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change From Baseline to Last Day of Dosing in Fasting HDL-c in Part B</measure>
    <time_frame>Predose, Days 7, 14, 21, and 28 Postdose</time_frame>
    <description>PD is the change from baseline to last day of dosing in fasting HDL-c in Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change From Baseline in Fasting Total Triglycerides Part A</measure>
    <time_frame>Predose, 24, 48, 96 Hours Postdose</time_frame>
    <description>PD is the change from baseline in fasting total triglycerides in Part A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change From Baseline to Last Day of Dosing in Fasting Total Triglycerides in Part B</measure>
    <time_frame>Predose, Days 7, 14, 21, and 28 Postdose</time_frame>
    <description>PD is the change from baseline to last day of dosing in fasting total triglycerides in Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change From Baseline to in Fasting Total Cholesterol in Part A</measure>
    <time_frame>Predose, 24, 28, 96 Hours Postdose</time_frame>
    <description>PD is the change from baseline in fasting total cholesterol in Part A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change From Baseline to Last Day of Dosing in Fasting Total Cholesterol in Part B</measure>
    <time_frame>Predose, Days 7, 14, 21, and 28 Postdose</time_frame>
    <description>PD is the change from baseline to last day of dosing in fasting total cholesterol in Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change From Baseline in Fasting Low-Density Lipoprotein Cholesterol (LDL-c) in Part A</measure>
    <time_frame>Predose, 24, 48, 96 Hours Postdose</time_frame>
    <description>PD is the change from baseline in fasting low-density lipoprotein cholesterol (LDL-c) Part A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change From Baseline to Last Day of Dosing in Fasting LDL-c in Part B</measure>
    <time_frame>Predose, Days 7, 14, 21, and 28 Postdose</time_frame>
    <description>PD is the change from baseline to last day of dosing in fasting LDL-c in Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of Simvastatin With/Without LY3202328 (LY) in Part B</measure>
    <time_frame>Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
    <description>PK: Cmax of Simvastatin with/without LY3202328 (LY) Co-administration in Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under Concentration Curve From Zero to Time (AUC [0-t]) of Simvastatin With/Without LY3202328 (LY) in Part B</measure>
    <time_frame>Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
    <description>PK: Area Under Concentration Curve From Zero to Time (AUC [0-t]) of Simvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of Atorvastatin With/Without LY3202328 (LY) in Part B</measure>
    <time_frame>Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
    <description>PK: Cmax of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC (0-t) of Atorvastatin With/Without LY3202328 (LY) in Part B</measure>
    <time_frame>Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
    <description>PK: AUC (0-t) of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Part A: LY3202328 (LY)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of 1 milligram (mg), 3 mg, 10 mg, 30 mg, 100 mg, 300mg, 600 mg LY3202328 orally while fasting, or 30 mg LY3202328 orally while fed in 4 periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY3202328 (LY)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A multiple ascending dose of 5 mg, 20 mg, 100 mg, and 300 mg LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3202328</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: LY3202328 (LY)</arm_group_label>
    <arm_group_label>Part B: LY3202328 (LY)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part B: LY3202328 (LY)</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part B: LY3202328 (LY)</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be healthy, as determined by medical history and physical examination&#xD;
&#xD;
          -  Male participants must be between 18 and 70 years of age and must agree to use a&#xD;
             reliable method of birth control during the study and 3 months following the last dose&#xD;
             of the investigational product&#xD;
&#xD;
          -  Female participants must be between 40 and 70 years old, and either postmenopausal or&#xD;
             with a hysterectomy, and not pregnant and not lactating&#xD;
&#xD;
          -  Be on a stable diet and exercise regimen for greater than (&gt;) 3 months prior&#xD;
&#xD;
          -  Have a body mass index (BMI) of 25.0 to 35.0 (Part A) or 27.0 to 40.0 (Part B)&#xD;
             kilograms per meter squared&#xD;
&#xD;
          -  Have fasting triglycerides (TG) between 150 and 499 milligrams per deciliter (mg/dL)&#xD;
             (Part B only)&#xD;
&#xD;
          -  Have a fasting low-density lipoprotein cholesterol (LDL-c) between 100 and 200 mg/dL&#xD;
             (Part B only)&#xD;
&#xD;
          -  Have estimated glomerular filtration rate greater than or equal to (≥) 60 milliliters&#xD;
             per minute/1.73 meter squared with no proteinuria&#xD;
&#xD;
          -  Be normotensive defined as supine systolic blood pressure (BP) less than or equal to&#xD;
             (≤) 150 millimeters of mercury (mm Hg) and diastolic BP ≤ 100 mm Hg, without the use&#xD;
             of any antihypertensive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are taking a statin, any proprotein convertase subtilisin/kexin type 9 (PCSK9)&#xD;
             medications, or have started taking other TG lowering agents (for example, niacin,&#xD;
             fish oils)&#xD;
&#xD;
          -  Are currently enrolled in a clinical trial involving an investigational product or&#xD;
             off-label use of a drug or device, or are concurrently enrolled in any other type of&#xD;
             medical research, or have participated in a clinical trial involving an&#xD;
             investigational product or non-approved use of a drug within the last 30 days or&#xD;
             within 5 half-lives&#xD;
&#xD;
          -  Have an abnormal electrocardiogram or corrected QT or are on antihypertensive&#xD;
             treatment&#xD;
&#xD;
          -  Have any current or prior history of significant cardiovascular disease&#xD;
&#xD;
          -  Show evidence of hepatitis C virus (HCV), Hepatitis B or other chronic liver disease&#xD;
&#xD;
          -  Have an alcohol intake that exceeds 7 units per week with no more than 3 units per&#xD;
             day, or are unwilling to stop alcohol consumption for the duration of the study (1&#xD;
             unit = 12 ounces or 360 mL of beer; 5 ounces or 150 mL of wine; 1.5 ounces or 45 mL of&#xD;
             distilled spirits), or are a regular user of known drugs of abuse&#xD;
&#xD;
          -  Have a history of untreated endocrine illness such as diabetes mellitus&#xD;
&#xD;
          -  Have been on medications or supplements for weight loss within 3 months&#xD;
&#xD;
          -  Have a history of active neuropsychiatric disease or on pharmacological therapy for&#xD;
             such conditions (Part B, only)&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Have been on medications that are known to inhibit cytochrome P450, family 3,&#xD;
             subfamily A (CYP3A) or P-glycoprotein (P-gp), or regularly consume grapefruit&#xD;
&#xD;
          -  Have donated blood of more than 500 mL within the last month&#xD;
&#xD;
          -  Smoke &gt;10 cigarettes per day or are unwilling to follow smoking rules&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>06219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/dyslipidemia/GSEA#?postal=</url>
    <description>A Study of LY3202328 in Overweight Healthy Participants and in Participants With Dyslipidemia</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <results_first_submitted>March 22, 2021</results_first_submitted>
  <results_first_submitted_qc>May 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2021</results_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: GSEA Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02714569/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: GSEA Protocol (a)</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02714569/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02714569/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Part A participants were divided into 2 cohorts. Within each cohort, participants were randomized to a treatment sequence (4 periods; up to 3 LY dose levels and at least one placebo). A 2-week washout occurred between each period. Part B participants were divided into 4 cohorts. Within each cohort, participants were randomized to LY or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: Cohort 1(C1), Sequence 1</title>
          <description>1 milligram (mg) of LY3202328 (LY) was taken orally first intervention, then 10 mg of LY was taken orally second intervention, then placebo was taken orally third intervention, then 600 mg of LY was taken orally fourth intervention.&#xD;
C1, Sequence 1: (1 mg LY, 10 mg LY, Placebo, 600 mg LY)</description>
        </group>
        <group group_id="P2">
          <title>Part A: C1, Sequence 2</title>
          <description>1 mg of LY was taken orally first intervention, then placebo was taken orally second intervention, then 100 mg of LY was taken orally third intervention, then 600 mg of LY was taken orally fourth intervention.&#xD;
C1, Sequence 2: (1 mg LY, Placebo, 100 mg LY, 600 mg LY)</description>
        </group>
        <group group_id="P3">
          <title>Part A: C1, Sequence 3</title>
          <description>Placebo was taken orally first intervention, then 10 mg LY was taken orally second intervention, then, 100 mg LY was taken orally third intervention, then placebo was taken orally fourth intervention.&#xD;
C1, Sequence 3: (Placebo, 10 mg LY, 100 mg LY, Placebo)</description>
        </group>
        <group group_id="P4">
          <title>Part A: Cohort 2 (C2), Sequence 1</title>
          <description>3 mg of LY was taken orally first intervention, then 30 mg of LY was taken orally second intervention, then placebo was taken orally third intervention, then 30 mg of LY fed was taken orally fourth intervention.&#xD;
C2, Sequence 1: (3 mg LY, 30 mg LY, Placebo, 30 mg LY Fed)</description>
        </group>
        <group group_id="P5">
          <title>Part A: C2, Sequence 2</title>
          <description>3 mg of LY was taken orally first intervention, then placebo was taken orally second intervention, then 300 mg of LY was taken orally third intervention, then placebo was taken orally fourth intervention.&#xD;
C2, Sequence 2: (3 mg LY, Placebo, 300 mg LY, Placebo)</description>
        </group>
        <group group_id="P6">
          <title>Part A: C2, Sequence 3</title>
          <description>Placebo was taken orally first intervention, then 30 mg of LY was taken orally second intervention, then 300 mg of LY was taken orally third intervention, then 30 mg of LY fed was taken orally fourth intervention.&#xD;
C2, Sequence 3: (Placebo, 30 mg LY, 300 mg LY, 30 mg LY Fed)</description>
        </group>
        <group group_id="P7">
          <title>Part B: C3 (Simvastatin [SS]/Atorvastatin[AS] + 5 mg LY)</title>
          <description>5 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
        </group>
        <group group_id="P8">
          <title>Part B: C4 (SS/AS + 20 mg LY)</title>
          <description>20 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
        </group>
        <group group_id="P9">
          <title>Part B: C5 (SS/AS + 100 mg LY)</title>
          <description>100 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
        </group>
        <group group_id="P10">
          <title>Part B: C6 (SS/AS + 300 mg LY)</title>
          <description>300 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
        </group>
        <group group_id="P11">
          <title>Part B: C3-C6 (SS/AS + Placebo)</title>
          <description>Participants were randomly assigned to multiple ascending doses of placebo instead of LY at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Positive Urine Drug Screen (UDS)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A Fourth Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4">An additional participant replaced a discontinued participant.</participants>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3">An additional participant replaced a discontinued participant.</participants>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Positive Urinary Drug Screen (UDS)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B (Overall)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Part A participants completed period 4 and were not in part B.</participants>
                <participants group_id="P2" count="0">Part A participants completed period 4 and were not in part B.</participants>
                <participants group_id="P3" count="0">Part A participants completed period 4 and were not in part B.</participants>
                <participants group_id="P4" count="0">Part A participants completed period 4 and were not in part B.</participants>
                <participants group_id="P5" count="0">Part A participants completed period 4 and were not in part B.</participants>
                <participants group_id="P6" count="0">Part A participants completed period 4 and were not in part B.</participants>
                <participants group_id="P7" count="8">Part B participants randomized to receive 5 mg of LY3202328 + atorvastatin/simvastatin.</participants>
                <participants group_id="P8" count="8">Part B participants randomized to receive 20 mg of LY3202328 + atorvastatin/simvastatin.</participants>
                <participants group_id="P9" count="8">Part B participants randomized to receive 100 mg of LY3202328 + atorvastatin/simvastatin.</participants>
                <participants group_id="P10" count="8">Part B participants randomized to receive 300 mg of LY3202328 + atorvastatin/simvastatin.</participants>
                <participants group_id="P11" count="8">Part B participants randomized to receive placebo instead of LY3202328 + atorvastatin/simvastatin.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least one dose of study drug in Part A and Part B.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A, C1, Sequence 1</title>
          <description>1 mg of LY3202328 (LY) was taken orally first intervention, then 10 mg of LY was taken orally second intervention, then placebo was taken orally third intervention, then 600 mg of LY was taken orally fourth intervention.&#xD;
C1, Sequence 1:&#xD;
(1 mg LY, 10 mg LY, Placebo, 600 mg LY)</description>
        </group>
        <group group_id="B2">
          <title>Part A, C1, Sequence 2</title>
          <description>1 mg of LY was taken orally first intervention, then placebo was taken orally second intervention, then 100 mg of LY was taken orally third intervention, then 600 mg of LY was taken orally fourth intervention.&#xD;
C1, Sequence 2:&#xD;
(1 mg LY, Placebo, 100 mg LY, 600 mg LY)</description>
        </group>
        <group group_id="B3">
          <title>Part A, C1, Sequence 3</title>
          <description>Placebo was taken orally first intervention, then 10 mg LY was taken orally second intervention, then, 100 mg LY was taken orally third intervention, then placebo was taken orally fourth intervention.&#xD;
C1, Sequence 3: (Placebo, 10 mg LY, 100 mg LY, Placebo)</description>
        </group>
        <group group_id="B4">
          <title>Part A, C2, Sequence 1</title>
          <description>3 mg of LY was taken orally first intervention, then 30 mg of LY was taken orally second intervention, then placebo was taken orally third intervention, then 30 mg of LY fed was taken orally fourth intervention&#xD;
C2, Sequence 1:&#xD;
3 mg LY, 30 mg LY, Placebo, 30 mg LY Fed</description>
        </group>
        <group group_id="B5">
          <title>Part A, C2, Sequence 2</title>
          <description>3 mg of LY was taken orally first intervention, then placebo was taken orally second intervention, then 300 mg of LY was taken orally third intervention, then placebo was taken orally fourth intervention.&#xD;
C2, Sequence 2:&#xD;
3 mg LY, Placebo, 300 mg LY, Placebo</description>
        </group>
        <group group_id="B6">
          <title>Part A, C2, Sequence 3</title>
          <description>Placebo was taken orally first intervention, then 30 mg of LY was taken orally second intervention, then 300 mg of LY was taken orally third intervention, then 30 mg of LY fed was taken orally fourth intervention.&#xD;
C2, Sequence 3:&#xD;
Placebo, 30 mg LY, 300 mg LY, 30 mg LY Fed</description>
        </group>
        <group group_id="B7">
          <title>Part B: SS/AS/Placebo</title>
          <description>Participants were randomly assigned to multiple ascending doses of placebo instead of LY at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
        </group>
        <group group_id="B8">
          <title>Part B: SS/AS/5 mg LY</title>
          <description>5 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
        </group>
        <group group_id="B9">
          <title>Part B: SS/AS/20 mg LY</title>
          <description>20 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
        </group>
        <group group_id="B10">
          <title>Part B: SS/AS/100 mg LY</title>
          <description>100 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
        </group>
        <group group_id="B11">
          <title>Part B: SS/AS/300 mg LY</title>
          <description>300 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="8"/>
            <count group_id="B11" value="8"/>
            <count group_id="B12" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" spread="8.02"/>
                    <measurement group_id="B2" value="56.0" spread="12.12"/>
                    <measurement group_id="B3" value="58.5" spread="4.04"/>
                    <measurement group_id="B4" value="34.0" spread="13.53"/>
                    <measurement group_id="B5" value="38.3" spread="22.50"/>
                    <measurement group_id="B6" value="54.7" spread="17.21"/>
                    <measurement group_id="B7" value="54.0" spread="9.12"/>
                    <measurement group_id="B8" value="50.5" spread="12.76"/>
                    <measurement group_id="B9" value="46.8" spread="13.13"/>
                    <measurement group_id="B10" value="55.0" spread="10.18"/>
                    <measurement group_id="B11" value="36.9" spread="10.80"/>
                    <measurement group_id="B12" value="48.7" spread="13.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B</title>
        <description>Number of participants with one or more SAEs in Part A and Part B. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
        <time_frame>Baseline, Up to 42 Days</time_frame>
        <population>All participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants were randomly assigned to placebo instead of LY in one of the first three periods.</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1 mg LY3202328 (LY)</title>
            <description>1 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O3">
            <title>Part A: 3 mg LY</title>
            <description>3 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O4">
            <title>Part A: 10 mg LY</title>
            <description>10 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O5">
            <title>Part A: 30 mg LY</title>
            <description>30 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O6">
            <title>Part A: 100 mg LY</title>
            <description>100 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O7">
            <title>Part A: 300 mg LY</title>
            <description>300 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O8">
            <title>Part A: 30 mg LY Fed</title>
            <description>30 mg (fed) of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O9">
            <title>Part A: 600 mg LY</title>
            <description>600 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O10">
            <title>Part B: SS/AS/Placebo</title>
            <description>Participants were randomly assigned to multiple ascending doses of placebo instead of LY at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O11">
            <title>Part B: SS/AS/5 mg of LY</title>
            <description>5 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O12">
            <title>Part B: SS/AS/20 mg of LY</title>
            <description>20 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O13">
            <title>Part B: SS/AS/100 mg of LY</title>
            <description>100 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O14">
            <title>Part B: SS/AS/300 mg of LY</title>
            <description>300 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B</title>
          <description>Number of participants with one or more SAEs in Part A and Part B. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
          <population>All participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="8"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part A After a Single Dose</title>
        <description>Pharmacokinetics (PK) is the maximum plasma concentration (Cmax) of LY3202328 Part A after a single dose.</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part A after a single dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 1 mg LY</title>
            <description>1 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O2">
            <title>Part A: 3 mg LY</title>
            <description>3 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O3">
            <title>Part A: 10 mg LY</title>
            <description>10 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O4">
            <title>Part A: 30 mg LY</title>
            <description>30 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O5">
            <title>Part A: 100 mg LY</title>
            <description>100 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O6">
            <title>Part A: 300 mg LY</title>
            <description>300 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O7">
            <title>Part A: 600 mg LY</title>
            <description>600 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O8">
            <title>Part A: 30 mg LY Fed</title>
            <description>30 mg of LY (fed) was taken orally in one of four periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part A After a Single Dose</title>
          <description>Pharmacokinetics (PK) is the maximum plasma concentration (Cmax) of LY3202328 Part A after a single dose.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part A after a single dose.</population>
          <units>nanogram/milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.258" spread="21.11"/>
                    <measurement group_id="O2" value="105.023" spread="26.66"/>
                    <measurement group_id="O3" value="340.829" spread="28.99"/>
                    <measurement group_id="O4" value="581.782" spread="32.29"/>
                    <measurement group_id="O5" value="1600.953" spread="40.01"/>
                    <measurement group_id="O6" value="1632.595" spread="42.84"/>
                    <measurement group_id="O7" value="2866.855" spread="51.29"/>
                    <measurement group_id="O8" value="1105.999" spread="18.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Geometric Mean Fed/Fasted Ratio of LY3202328 Cmax at 30 mg</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Analyses were based on a pre-defined non-inferiority margin</non_inferiority_desc>
            <param_type>Least Square Means Percentage</param_type>
            <param_value>204.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>161.9</ci_lower_limit>
            <ci_upper_limit>259.0</ci_upper_limit>
            <estimate_desc>Analysis was the estimate of the ratio fasted versus fed.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Steady State Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part B</title>
        <description>PK is the maximum plasma concentration of LY3202328 (Cmax) at steady state in Part B.</description>
        <time_frame>Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: 5 mg LY</title>
            <description>5 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part B: 20 mg LY</title>
            <description>20 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part B: 100 mg LY</title>
            <description>100 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part B: 300 mg LY</title>
            <description>300 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Steady State Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part B</title>
          <description>PK is the maximum plasma concentration of LY3202328 (Cmax) at steady state in Part B.</description>
          <population>All randomized participants who received at least one dose of study drug in Part B.</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445.858" spread="32.78"/>
                    <measurement group_id="O2" value="882.125" spread="32.81"/>
                    <measurement group_id="O3" value="3687.167" spread="34.83"/>
                    <measurement group_id="O4" value="3209.396" spread="37.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Area Under the Serum Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY3202328 (LY) in Part A After a Single Dose</title>
        <description>PK is the area under the serum concentration time curve from zero to Infinity (AUC[0-∞]) of LY3202328 in Part A after a single dose.</description>
        <time_frame>Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part A after a single dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 1 mg LY</title>
            <description>1 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O2">
            <title>Part A: 3 mg of LY</title>
            <description>3 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O3">
            <title>Part A: 10 mg LY</title>
            <description>10 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O4">
            <title>Part A: 30 mg LY</title>
            <description>30 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O5">
            <title>Part A: 100 mg of LY</title>
            <description>100 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O6">
            <title>Part A: 300 mg LY</title>
            <description>300 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O7">
            <title>Part A: 600 mg LY</title>
            <description>600 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O8">
            <title>Part A: 30 mg LY Fed</title>
            <description>30 mg of LY was taken orally in one of four periods.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under the Serum Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY3202328 (LY) in Part A After a Single Dose</title>
          <description>PK is the area under the serum concentration time curve from zero to Infinity (AUC[0-∞]) of LY3202328 in Part A after a single dose.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part A after a single dose.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Geometric mean/Coefficient Variation (CV) was not calculated due to n=1. Minimum and maximum values = 1607.0, 1607.0.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Geometric mean/CV was not calculated due to small sample size n=3. Minimum and maximum values = 2632.0, 3047.0</measurement>
                    <measurement group_id="O3" value="7726.17" spread="45.23"/>
                    <measurement group_id="O4" value="17018.43" spread="62.60"/>
                    <measurement group_id="O5" value="55406.24" spread="41.35"/>
                    <measurement group_id="O6" value="66185.70" spread="71.44"/>
                    <measurement group_id="O7" value="NA" spread="NA">Geometric mean/CV was not calculated due to n=2. Minimum and maximum values = 63062.0, 83978.0.</measurement>
                    <measurement group_id="O8" value="28415.22" spread="56.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Geometric Mean Fed/Fasted Ratio of LY3202328 AUC(0-inf) at 30 mg</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Analyses were based on a pre-defined non-inferiority margin</non_inferiority_desc>
            <param_type>Least Squares Mean Percentage</param_type>
            <param_value>193.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>144.7</ci_lower_limit>
            <ci_upper_limit>258.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Steady State Area Under the Serum Concentration-Time Curve During the Dosing Interval (AUCτ) of LY3202328 (LY) in Part B</title>
        <description>PK is the area under the serum concentration-time curve (AUCτ) of LY3202328 at steady state during the dosing interval in Part B.</description>
        <time_frame>Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: 5 mg LY</title>
            <description>5 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part B: 20 mg LY</title>
            <description>20 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part B: 100 mg LY</title>
            <description>100 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part B: 300 mg LY</title>
            <description>300 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Steady State Area Under the Serum Concentration-Time Curve During the Dosing Interval (AUCτ) of LY3202328 (LY) in Part B</title>
          <description>PK is the area under the serum concentration-time curve (AUCτ) of LY3202328 at steady state during the dosing interval in Part B.</description>
          <population>All randomized participants who received at least one dose of study drug in Part B.</population>
          <units>hour*nanogram/milliliter(hr*ng/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7587.24" spread="38.612"/>
                    <measurement group_id="O2" value="13362.44" spread="44.984"/>
                    <measurement group_id="O3" value="67499.80" spread="37.465"/>
                    <measurement group_id="O4" value="50774.85" spread="43.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Time to Maximum Concentration (Tmax) of LY3202328 (LY) in Part A</title>
        <description>PK is the time to maximum concentration (Tmax) of LY3202328 in Part A</description>
        <time_frame>Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part A.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: 1 mg LY</title>
            <description>1 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O2">
            <title>Part A: 3 mg LY</title>
            <description>3 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O3">
            <title>Part A: 10 mg LY</title>
            <description>10 mg of LY or placebo was taken orally in one of four periods.</description>
          </group>
          <group group_id="O4">
            <title>Part A: 30 mg LY</title>
            <description>30 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O5">
            <title>Part A: 100 mg LY</title>
            <description>100 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O6">
            <title>Part A: 300 mg LY</title>
            <description>300 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O7">
            <title>Part A: 600 mg LY</title>
            <description>600 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O8">
            <title>Part A: 30 mg LY Fed</title>
            <description>30 mg of LY (fed) was taken orally in one of four periods.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Time to Maximum Concentration (Tmax) of LY3202328 (LY) in Part A</title>
          <description>PK is the time to maximum concentration (Tmax) of LY3202328 in Part A</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part A.</population>
          <units>hour (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.52" lower_limit="2.0" upper_limit="6.2"/>
                    <measurement group_id="O3" value="4.0" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="4.00" lower_limit="3.0" upper_limit="4.1"/>
                    <measurement group_id="O5" value="6.00" lower_limit="2.0" upper_limit="8.0"/>
                    <measurement group_id="O6" value="4.02" lower_limit="3.0" upper_limit="8.0"/>
                    <measurement group_id="O7" value="4.00" lower_limit="2.0" upper_limit="24.0"/>
                    <measurement group_id="O8" value="5.00" lower_limit="4.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Steady State Tmax of LY3202328 (LY) in Part B</title>
        <description>PK is the Tmax of LY3202328 at steady state in Part B.</description>
        <time_frame>Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: 5 mg LY</title>
            <description>5 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part B: 20 mg LY</title>
            <description>20 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part B: 100 mg LY</title>
            <description>100 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part B: 300 mg LY</title>
            <description>300 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Steady State Tmax of LY3202328 (LY) in Part B</title>
          <description>PK is the Tmax of LY3202328 at steady state in Part B.</description>
          <population>All randomized participants who received at least one dose of study drug in Part B.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="4.20" lower_limit="4.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="3.00" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O4" value="3.04" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics (PD): Change From Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A</title>
        <description>Pharmacodynamics (PD) is the change from Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A.</description>
        <time_frame>Predose, 24, 48, 96 Hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable fasting HDL-c data in Part A.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants were randomly assigned to placebo instead of LY in one of the first three periods.</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1 mg LY</title>
            <description>1 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O3">
            <title>Part A: 3 mg LY</title>
            <description>3 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O4">
            <title>Part A: 10 mg LY</title>
            <description>10 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O5">
            <title>Part A: 30 mg LY</title>
            <description>30 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O6">
            <title>Part A: 100 mg LY</title>
            <description>100 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O7">
            <title>Part A: 300 mg LY</title>
            <description>300 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O8">
            <title>Part A: 600 mg LY</title>
            <description>600 mg of LY was taken orally in one of four periods..</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics (PD): Change From Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A</title>
          <description>Pharmacodynamics (PD) is the change from Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable fasting HDL-c data in Part A.</population>
          <units>millimole/Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.1155"/>
                    <measurement group_id="O2" value="-0.030" spread="0.0842"/>
                    <measurement group_id="O3" value="-0.043" spread="0.0454"/>
                    <measurement group_id="O4" value="-0.047" spread="0.0740"/>
                    <measurement group_id="O5" value="-0.026" spread="0.0433"/>
                    <measurement group_id="O6" value="0.052" spread="0.1099"/>
                    <measurement group_id="O7" value="-0.004" spread="0.0684"/>
                    <measurement group_id="O8" value="0.010" spread="0.0232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037" spread="0.1560"/>
                    <measurement group_id="O2" value="-0.039" spread="0.0217"/>
                    <measurement group_id="O3" value="0.009" spread="0.1387"/>
                    <measurement group_id="O4" value="-0.043" spread="0.0950"/>
                    <measurement group_id="O5" value="-0.026" spread="0.1010"/>
                    <measurement group_id="O6" value="0.019" spread="0.0978"/>
                    <measurement group_id="O7" value="-0.009" spread="0.1551"/>
                    <measurement group_id="O8" value="-0.052" spread="0.0755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.074" spread="0.1258"/>
                    <measurement group_id="O2" value="-0.073" spread="0.1241"/>
                    <measurement group_id="O3" value="-0.086" spread="0.0892"/>
                    <measurement group_id="O4" value="-0.134" spread="0.0553"/>
                    <measurement group_id="O5" value="-0.030" spread="0.1304"/>
                    <measurement group_id="O6" value="-0.091" spread="0.1206"/>
                    <measurement group_id="O7" value="-0.082" spread="0.1487"/>
                    <measurement group_id="O8" value="-0.005" spread="0.1411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Change From Baseline to Last Day of Dosing in Fasting HDL-c in Part B</title>
        <description>PD is the change from baseline to last day of dosing in fasting HDL-c in Part B.</description>
        <time_frame>Predose, Days 7, 14, 21, and 28 Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>A multiple ascending dose of placebo instead of LY at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part B: 5 mg LY</title>
            <description>5 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part B: 20 mg LY</title>
            <description>20 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part B: 100 mg LY</title>
            <description>100 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part B: 300 mg LY</title>
            <description>300 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) week prior to treatment and on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Change From Baseline to Last Day of Dosing in Fasting HDL-c in Part B</title>
          <description>PD is the change from baseline to last day of dosing in fasting HDL-c in Part B.</description>
          <population>All randomized participants who received at least one dose of study drug in Part B.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.1169"/>
                    <measurement group_id="O2" value="-0.010" spread="0.1165"/>
                    <measurement group_id="O3" value="-0.101" spread="0.0812"/>
                    <measurement group_id="O4" value="-0.107" spread="0.1894"/>
                    <measurement group_id="O5" value="-0.101" spread="0.0621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Change From Baseline in Fasting Total Triglycerides Part A</title>
        <description>PD is the change from baseline in fasting total triglycerides in Part A.</description>
        <time_frame>Predose, 24, 48, 96 Hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable fasting triglyceride data in Part A.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants were randomly assigned to placebo instead of LY in one of the first three periods.</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1 mg LY</title>
            <description>1 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O3">
            <title>Part A: 3 mg LY</title>
            <description>3 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O4">
            <title>Part A: 10 mg LY</title>
            <description>10 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O5">
            <title>Part A: 30 mg LY</title>
            <description>30 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O6">
            <title>Part A: 100 mg LY</title>
            <description>100 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O7">
            <title>Part A: 300 mg LY</title>
            <description>300 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O8">
            <title>Part A: 600 mg LY</title>
            <description>600 mg of LY was taken orally in one of four periods.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Change From Baseline in Fasting Total Triglycerides Part A</title>
          <description>PD is the change from baseline in fasting total triglycerides in Part A.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable fasting triglyceride data in Part A.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.276" spread="0.2043"/>
                    <measurement group_id="O2" value="-0.397" spread="0.2877"/>
                    <measurement group_id="O3" value="-0.190" spread="0.1491"/>
                    <measurement group_id="O4" value="-0.386" spread="0.2766"/>
                    <measurement group_id="O5" value="-0.311" spread="0.2831"/>
                    <measurement group_id="O6" value="-0.523" spread="0.5801"/>
                    <measurement group_id="O7" value="-0.064" spread="0.1455"/>
                    <measurement group_id="O8" value="-0.302" spread="0.2318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.320" spread="0.3162"/>
                    <measurement group_id="O2" value="-0.269" spread="0.2260"/>
                    <measurement group_id="O3" value="-0.115" spread="0.2643"/>
                    <measurement group_id="O4" value="-0.260" spread="0.3382"/>
                    <measurement group_id="O5" value="-0.418" spread="0.3290"/>
                    <measurement group_id="O6" value="-0.766" spread="0.5870"/>
                    <measurement group_id="O7" value="-0.226" spread="0.3646"/>
                    <measurement group_id="O8" value="-0.198" spread="0.1345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.239" spread="0.3227"/>
                    <measurement group_id="O2" value="-0.209" spread="0.6817"/>
                    <measurement group_id="O3" value="-0.132" spread="0.2349"/>
                    <measurement group_id="O4" value="0.013" spread="0.7179"/>
                    <measurement group_id="O5" value="-0.331" spread="0.4343"/>
                    <measurement group_id="O6" value="-0.455" spread="0.5144"/>
                    <measurement group_id="O7" value="-0.326" spread="0.3549"/>
                    <measurement group_id="O8" value="0.158" spread="0.6773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Change From Baseline to Last Day of Dosing in Fasting Total Triglycerides in Part B</title>
        <description>PD is the change from baseline to last day of dosing in fasting total triglycerides in Part B.</description>
        <time_frame>Predose, Days 7, 14, 21, and 28 Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>A multiple ascending dose of placebo instead of LY at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part B: 5 mg LY</title>
            <description>5 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part B: 20 mg LY</title>
            <description>20 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part B: 100 mg LY</title>
            <description>100 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part B: 300 mg LY</title>
            <description>300 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Change From Baseline to Last Day of Dosing in Fasting Total Triglycerides in Part B</title>
          <description>PD is the change from baseline to last day of dosing in fasting total triglycerides in Part B.</description>
          <population>All randomized participants who received at least one dose of study drug in Part B.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.205" spread="0.6757"/>
                    <measurement group_id="O2" value="-0.131" spread="0.2720"/>
                    <measurement group_id="O3" value="-0.231" spread="0.5383"/>
                    <measurement group_id="O4" value="0.020" spread="0.6281"/>
                    <measurement group_id="O5" value="-0.480" spread="0.5235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Change From Baseline to in Fasting Total Cholesterol in Part A</title>
        <description>PD is the change from baseline in fasting total cholesterol in Part A.</description>
        <time_frame>Predose, 24, 28, 96 Hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable fasting total cholesterol data in Part A.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants were randomly assigned to placebo instead of LY in one of the first three periods.</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1 mg LY</title>
            <description>1 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O3">
            <title>Part A: 3 mg LY</title>
            <description>3 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O4">
            <title>Part A: 10 mg LY</title>
            <description>10 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O5">
            <title>Part A: 30 mg LY</title>
            <description>30 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O6">
            <title>Part A: 100 mg LY</title>
            <description>100 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O7">
            <title>Part A: 300 mg LY</title>
            <description>300 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O8">
            <title>Part A: 600 mg LY</title>
            <description>600 mg of LY was taken orally in one of four periods.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Change From Baseline to in Fasting Total Cholesterol in Part A</title>
          <description>PD is the change from baseline in fasting total cholesterol in Part A.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable fasting total cholesterol data in Part A.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.085" spread="0.3075"/>
                    <measurement group_id="O2" value="-0.186" spread="0.2699"/>
                    <measurement group_id="O3" value="-0.013" spread="0.2850"/>
                    <measurement group_id="O4" value="-0.203" spread="0.2157"/>
                    <measurement group_id="O5" value="0.073" spread="0.1863"/>
                    <measurement group_id="O6" value="0.285" spread="0.1903"/>
                    <measurement group_id="O7" value="0.203" spread="0.2421"/>
                    <measurement group_id="O8" value="0.093" spread="0.1560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.085" spread="0.4618"/>
                    <measurement group_id="O2" value="-0.436" spread="0.2608"/>
                    <measurement group_id="O3" value="-0.030" spread="0.2218"/>
                    <measurement group_id="O4" value="-0.376" spread="0.2321"/>
                    <measurement group_id="O5" value="-0.013" spread="0.3981"/>
                    <measurement group_id="O6" value="0.091" spread="0.3654"/>
                    <measurement group_id="O7" value="0.134" spread="0.5446"/>
                    <measurement group_id="O8" value="-0.026" spread="0.4719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.318" spread="0.4288"/>
                    <measurement group_id="O2" value="-0.527" spread="0.3262"/>
                    <measurement group_id="O3" value="-0.207" spread="0.2949"/>
                    <measurement group_id="O4" value="-0.609" spread="0.2635"/>
                    <measurement group_id="O5" value="-0.199" spread="0.4732"/>
                    <measurement group_id="O6" value="-0.317" spread="0.6296"/>
                    <measurement group_id="O7" value="-0.155" spread="0.4826"/>
                    <measurement group_id="O8" value="-0.041" spread="0.6020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Change From Baseline to Last Day of Dosing in Fasting Total Cholesterol in Part B</title>
        <description>PD is the change from baseline to last day of dosing in fasting total cholesterol in Part B.</description>
        <time_frame>Predose, Days 7, 14, 21, and 28 Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part B: 5 mg LY</title>
            <description>5 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part B: 20 mg LY</title>
            <description>20 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part B: 100 mg LY</title>
            <description>100 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part B: 300 mg LY</title>
            <description>300 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Change From Baseline to Last Day of Dosing in Fasting Total Cholesterol in Part B</title>
          <description>PD is the change from baseline to last day of dosing in fasting total cholesterol in Part B.</description>
          <population>All randomized participants who received at least one dose of study drug in Part B.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.206" spread="0.3615"/>
                    <measurement group_id="O2" value="0.118" spread="0.3840"/>
                    <measurement group_id="O3" value="0.183" spread="0.4681"/>
                    <measurement group_id="O4" value="0.174" spread="0.4963"/>
                    <measurement group_id="O5" value="-0.190" spread="0.4425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Change From Baseline in Fasting Low-Density Lipoprotein Cholesterol (LDL-c) in Part A</title>
        <description>PD is the change from baseline in fasting low-density lipoprotein cholesterol (LDL-c) Part A.</description>
        <time_frame>Predose, 24, 48, 96 Hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable LDL-c data in Part A.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo</title>
            <description>Participants were randomly assigned to placebo instead of LY in one of the first three periods.</description>
          </group>
          <group group_id="O2">
            <title>Part A: 1 mg LY</title>
            <description>1 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O3">
            <title>Part A: 3 mg LY</title>
            <description>3 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O4">
            <title>Part A: 10 mg LY</title>
            <description>10 mg of LY was taken orally in one of four periods..</description>
          </group>
          <group group_id="O5">
            <title>Part A: 30 mg LY</title>
            <description>30 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O6">
            <title>Part A: 100 mg LY</title>
            <description>100 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O7">
            <title>Part A: 300 mg LY</title>
            <description>300 mg of LY was taken orally in one of four periods.</description>
          </group>
          <group group_id="O8">
            <title>Part A: 600 mg LY</title>
            <description>600 mg of LY was taken orally in one of four periods.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Change From Baseline in Fasting Low-Density Lipoprotein Cholesterol (LDL-c) in Part A</title>
          <description>PD is the change from baseline in fasting low-density lipoprotein cholesterol (LDL-c) Part A.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable LDL-c data in Part A.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.231" spread="0.2513"/>
                    <measurement group_id="O2" value="0.025" spread="0.2205"/>
                    <measurement group_id="O3" value="0.117" spread="0.2400"/>
                    <measurement group_id="O4" value="0.020" spread="0.2328"/>
                    <measurement group_id="O5" value="0.241" spread="0.1594"/>
                    <measurement group_id="O6" value="0.471" spread="0.3418"/>
                    <measurement group_id="O7" value="0.236" spread="0.2429"/>
                    <measurement group_id="O8" value="0.163" spread="0.1608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.111" spread="0.4026"/>
                    <measurement group_id="O2" value="-0.275" spread="0.3004"/>
                    <measurement group_id="O3" value="0.013" spread="0.2093"/>
                    <measurement group_id="O4" value="-0.214" spread="0.2378"/>
                    <measurement group_id="O5" value="0.203" spread="0.3400"/>
                    <measurement group_id="O6" value="0.419" spread="0.3293"/>
                    <measurement group_id="O7" value="0.245" spread="0.3457"/>
                    <measurement group_id="O8" value="-0.001" spread="0.3891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.109" spread="0.4147"/>
                    <measurement group_id="O2" value="-0.358" spread="0.4170"/>
                    <measurement group_id="O3" value="-0.061" spread="0.1747"/>
                    <measurement group_id="O4" value="-0.481" spread="0.3681"/>
                    <measurement group_id="O5" value="-0.018" spread="0.3048"/>
                    <measurement group_id="O6" value="-0.020" spread="0.6327"/>
                    <measurement group_id="O7" value="0.075" spread="0.2565"/>
                    <measurement group_id="O8" value="0.038" spread="0.6305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Change From Baseline to Last Day of Dosing in Fasting LDL-c in Part B</title>
        <description>PD is the change from baseline to last day of dosing in fasting LDL-c in Part B.</description>
        <time_frame>Predose, Days 7, 14, 21, and 28 Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Placebo</title>
            <description>Participants were randomly assigned to multiple ascending doses of placebo instead of LY at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part B: 5 mg LY</title>
            <description>5 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part B: 20 mg LY</title>
            <description>20 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Part B: 100 mg LY</title>
            <description>100 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
          <group group_id="O5">
            <title>Part B: 300 mg LY</title>
            <description>5 mg of LY taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Change From Baseline to Last Day of Dosing in Fasting LDL-c in Part B</title>
          <description>PD is the change from baseline to last day of dosing in fasting LDL-c in Part B.</description>
          <population>All randomized participants who received at least one dose of study in Part B.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.103" spread="0.4114"/>
                    <measurement group_id="O2" value="0.184" spread="0.3419"/>
                    <measurement group_id="O3" value="0.388" spread="0.4876"/>
                    <measurement group_id="O4" value="0.227" spread="0.4494"/>
                    <measurement group_id="O5" value="0.131" spread="0.4225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Cmax of Simvastatin With/Without LY3202328 (LY) in Part B</title>
        <description>PK: Cmax of Simvastatin with/without LY3202328 (LY) Co-administration in Part B.</description>
        <time_frame>Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin With LY (Test)</title>
            <description>A single simvastatin test dose was taken fasted a week prior to LY treatment initiation, and on Day 29 after initiation of LY daily dosing (coadministered with LY).</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin Alone (Reference)</title>
            <description>A single simvastatin reference dose was taken fasted a week prior to LY treatment initiation, and on Day 29 after initiation of LY daily dosing without LY.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Cmax of Simvastatin With/Without LY3202328 (LY) in Part B</title>
          <description>PK: Cmax of Simvastatin with/without LY3202328 (LY) Co-administration in Part B.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part B.</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.906" spread="18.72"/>
                    <measurement group_id="O2" value="2.061" spread="71.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.388" spread="58.17"/>
                    <measurement group_id="O2" value="3.374" spread="52.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.576" spread="19.35"/>
                    <measurement group_id="O2" value="3.274" spread="26.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.634" spread="55.59"/>
                    <measurement group_id="O2" value="4.303" spread="25.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.221" spread="58.78"/>
                    <measurement group_id="O2" value="1.979" spread="55.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B Placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Square Means Ratio (%)</param_type>
            <param_value>141.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.9</ci_lower_limit>
            <ci_upper_limit>293.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 5 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Square Means Ratio (%)</param_type>
            <param_value>70.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.9</ci_lower_limit>
            <ci_upper_limit>157.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 20 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Square Means Ratio (%)</param_type>
            <param_value>109.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.8</ci_lower_limit>
            <ci_upper_limit>119.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 100 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Square Means Ratio (%)</param_type>
            <param_value>107.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68.1</ci_lower_limit>
            <ci_upper_limit>170.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 300 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>213.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>200.3</ci_lower_limit>
            <ci_upper_limit>227.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B Overall</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Square Means Ratio (%)</param_type>
            <param_value>115.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.2</ci_lower_limit>
            <ci_upper_limit>146.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Area Under Concentration Curve From Zero to Time (AUC [0-t]) of Simvastatin With/Without LY3202328 (LY) in Part B</title>
        <description>PK: Area Under Concentration Curve From Zero to Time (AUC [0-t]) of Simvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.</description>
        <time_frame>Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin With LY (Test)</title>
            <description>A single simvastatin test dose was taken fasted a week prior to LY treatment initiation, and on Day 29 after initiation of LY daily dosing (coadministered with LY).</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin Alone (Reference)</title>
            <description>A single simvastatin reference dose was taken fasted a week prior to LY treatment initiation, and on Day 29 after initiation of LY daily dosing without LY.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under Concentration Curve From Zero to Time (AUC [0-t]) of Simvastatin With/Without LY3202328 (LY) in Part B</title>
          <description>PK: Area Under Concentration Curve From Zero to Time (AUC [0-t]) of Simvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part B.</population>
          <units>hr*ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.648" spread="38.82"/>
                    <measurement group_id="O2" value="6.250" spread="61.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.668" spread="42.96"/>
                    <measurement group_id="O2" value="9.287" spread="57.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.697" spread="26.81"/>
                    <measurement group_id="O2" value="7.960" spread="32.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.269" spread="53.78"/>
                    <measurement group_id="O2" value="10.434" spread="26.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.908" spread="60.19"/>
                    <measurement group_id="O2" value="8.951" spread="61.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B Placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>155</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.6</ci_lower_limit>
            <ci_upper_limit>274.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 5 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>71.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.7</ci_lower_limit>
            <ci_upper_limit>125.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 20 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratios (%)</param_type>
            <param_value>122.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.7</ci_lower_limit>
            <ci_upper_limit>165.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 100 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>136.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.8</ci_lower_limit>
            <ci_upper_limit>207.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 300 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>132.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.5</ci_lower_limit>
            <ci_upper_limit>194.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B Overall</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>112.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.2</ci_lower_limit>
            <ci_upper_limit>135.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Cmax of Atorvastatin With/Without LY3202328 (LY) in Part B</title>
        <description>PK: Cmax of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B.</description>
        <time_frame>Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin With LY (Test)</title>
            <description>A single atorvastatin test dose was taken fasted a week prior to LY treatment initiation, and on Day 29 after initiation of LY daily dosing (coadministered with LY).</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin Alone (Reference)</title>
            <description>A single atorvastatin reference dose was taken fasted a week prior to LY treatment initiation, and on Day 29 after initiation of LY daily dosing without LY.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Cmax of Atorvastatin With/Without LY3202328 (LY) in Part B</title>
          <description>PK: Cmax of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part B.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.479" spread="20.58"/>
                    <measurement group_id="O2" value="3.575" spread="30.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.840" spread="27.96"/>
                    <measurement group_id="O2" value="3.621" spread="82.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.238" spread="38.05"/>
                    <measurement group_id="O2" value="1.286" spread="45.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.511" spread="32.17"/>
                    <measurement group_id="O2" value="3.105" spread="51.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.489" spread="42.11"/>
                    <measurement group_id="O2" value="1.376" spread="59.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B Placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>97.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.4</ci_lower_limit>
            <ci_upper_limit>117.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>57.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.3</ci_lower_limit>
            <ci_upper_limit>106.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 20 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>96.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>66.8</ci_lower_limit>
            <ci_upper_limit>138.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 100 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>80.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>45.8</ci_lower_limit>
            <ci_upper_limit>142.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 300 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>108.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.2</ci_lower_limit>
            <ci_upper_limit>291.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B Overall</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>87.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.4</ci_lower_limit>
            <ci_upper_limit>114.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: AUC (0-t) of Atorvastatin With/Without LY3202328 (LY) in Part B</title>
        <description>PK: AUC (0-t) of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.</description>
        <time_frame>Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin With LY (Test)</title>
            <description>A single atorvastatin test dose was taken fasted a week prior to LY treatment initiation, and on Day 29 after initiation of LY daily dosing (coadministered with LY).</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin Alone (Reference)</title>
            <description>A single atorvastatin reference dose was taken fasted a week prior to LY treatment initiation, and on Day 29 after initiation of LY daily dosing without LY.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: AUC (0-t) of Atorvastatin With/Without LY3202328 (LY) in Part B</title>
          <description>PK: AUC (0-t) of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable PK data in Part B.</population>
          <units>hr*ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.874" spread="32.81"/>
                    <measurement group_id="O2" value="16.518" spread="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.311" spread="6.35"/>
                    <measurement group_id="O2" value="14.913" spread="48.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.921" spread="57.94"/>
                    <measurement group_id="O2" value="7.952" spread="63.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.983" spread="38.63"/>
                    <measurement group_id="O2" value="13.207" spread="61.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg LY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.748" spread="50.04"/>
                    <measurement group_id="O2" value="9.111" spread="36.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B Placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Square Means Ratio (%)</param_type>
            <param_value>96.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.2</ci_lower_limit>
            <ci_upper_limit>102.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 5 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>90.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.8</ci_lower_limit>
            <ci_upper_limit>137.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 20 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Square Means Ratio (%)</param_type>
            <param_value>99.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>75.9</ci_lower_limit>
            <ci_upper_limit>131.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 100 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Square Means Ratio (%)</param_type>
            <param_value>91.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.5</ci_lower_limit>
            <ci_upper_limit>122.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B 300 mg LY</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis testing</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>87.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.0</ci_lower_limit>
            <ci_upper_limit>180.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Part B Overall</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Ratio estimate without hypothesis</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>93.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.8</ci_lower_limit>
            <ci_upper_limit>106.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline to End of Study (Up to 10 Weeks)</time_frame>
      <desc>The safety population are all participants part A and part B combined who received at least one dose of study drug. Several participants received placebo for a second time during the fourth dosing interval, so these participants had 2 placebo-dosing periods.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants were randomly assigned to placebo instead of LY in one of the first three periods in Part A. Participants were randomly assigned to multiple ascending doses of placebo instead of LY at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29 in Part B.</description>
        </group>
        <group group_id="E2">
          <title>1 mg LY3202328 (LY)</title>
          <description>1 mg of LY was taken orally in one of four periods in Part A.</description>
        </group>
        <group group_id="E3">
          <title>3 mg LY</title>
          <description>3 mg of LY was taken orally in one of four periods in Part A.</description>
        </group>
        <group group_id="E4">
          <title>5 mg LY</title>
          <description>5 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29 in Part B.</description>
        </group>
        <group group_id="E5">
          <title>10 mg LY</title>
          <description>10 mg of LY was taken orally in one of four periods in Part A.</description>
        </group>
        <group group_id="E6">
          <title>20 mg LY</title>
          <description>20 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29 in Part B.</description>
        </group>
        <group group_id="E7">
          <title>30 mg LY</title>
          <description>30 mg of LY was taken orally in one of four periods in Part A.</description>
        </group>
        <group group_id="E8">
          <title>30 mg LY Fed</title>
          <description>30 mg of LY (fed) was taken orally in one of four periods in Part A.</description>
        </group>
        <group group_id="E9">
          <title>100 mg LY</title>
          <description>100 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29 in Part B.</description>
        </group>
        <group group_id="E10">
          <title>300 mg LY</title>
          <description>300 mg of LY was taken orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (SS/AS) one week prior to treatment and on Day 29 in Part B.</description>
        </group>
        <group group_id="E11">
          <title>600 mg of LY</title>
          <description>600 mg of LY was taken orally in one of four periods in Part A.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Alt increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pr interval prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in hip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Stiff neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatographic urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

